scholarly journals Conventional Cytology Is Not Beneficial for Predicting Peritoneal Recurrence after Curative Surgery for Gastric Cancer: Results of a Prospective Clinical Study

2014 ◽  
Vol 14 (1) ◽  
pp. 23 ◽  
Author(s):  
Ki-Kwan Kang ◽  
Hoon Hur ◽  
Cheul Su Byun ◽  
Young Bae Kim ◽  
Sang-Uk Han ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Study ◽  
Peritoneal Recurrence ◽  
Prospective Clinical Study ◽  
Curative Surgery ◽  
Conventional Cytology

Prospective study of peritoneal recurrence after curative surgery for gastric cancer

2003 ◽  
Vol 90 (9) ◽  
pp. 1113-1119 ◽  
Author(s):  
F. Roviello ◽  
D. Marrelli ◽  
G. de Manzoni ◽  
P. Morgagni ◽  
A. Di Leo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prospective Study ◽  
Peritoneal Recurrence ◽  
Curative Surgery

scholarly journals Extent of Serosal Changes Predicts Peritoneal Recurrence and Poor Prognosis After Curative Surgery for Gastric Cancer

Medicine ◽  
2015 ◽  
Vol 94 (42) ◽  
pp. e1750 ◽  
Author(s):  
Yue Kang ◽  
Shenglong Li ◽  
Qinghong Ge ◽  
Xinran Liu ◽  
Zhenyu Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Poor Prognosis ◽  
Peritoneal Recurrence ◽  
Curative Surgery

Macroscopic Serosal Classification Predicts Peritoneal Recurrence for Patients with Gastric Cancer Underwent Potentially Curative Surgery

2010 ◽  
Vol 18 (4) ◽  
pp. 1068-1080 ◽  
Author(s):  
Zhe Sun ◽  
Ying-ying Xu ◽  
Zhen-ning Wang ◽  
Zhi Zhu ◽  
Hao Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Recurrence ◽  
Curative Surgery

scholarly journals The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study

2003 ◽  
Vol 6 (3) ◽  
pp. 142-145 ◽  
Author(s):  
Yutaka Takahashi ◽  
Tetsuo Takeuchi ◽  
Junichi Sakamoto ◽  
Tetsuya Touge ◽  
Masayoshi Mai ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Study ◽  
Cancer Patients ◽  
Prospective Clinical Study ◽  
Gastric Cancer Patients

Phase III randomized controlled trial of hypotonic intraperitoneal cisplatin combined with oral UFT/PSK for the adjuvant treatment of gastric cancer invading the serosa

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4027-4027
Author(s):  
S. Tsujitani ◽  
H. Saito ◽  
S. Tatebe ◽  
M. Ikeguchi
Keyword(s):  
Gastric Cancer ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Abdominal Cavity ◽  
Oral Chemotherapy ◽  
Peritoneal Recurrence ◽  
Phase Iii ◽  
Curative Surgery ◽  
Curative Gastrectomy ◽  
Randomized Controlled

4027 Background: Peritoneal seeding is the most common pattern of recurrence in patients with gastric cancer invading the serosa who underwent curative gastrectomy. We developed hypotonic intraperitoneal cisplatin for preventing peritoneal recurrence in experimental models. Hypotonic cisplatin had a significant tumorcidal effect in vitro and in vivo. Hypotonic intraperitoneal cisplatin was tolerable in phase I clinical study. Now, we investigated the efficacy of the treatment in a multicenter prospective randomized controlled trial. Methods: 134 pts treated with curative resection for gastric cancer invading the serosa were randomized during surgery to one of 2 treatment arms. As per protocol, eligibility was confirmed by pathology and treatment course in 108 pts as follows: A -Hypotonic intraperitoneal cisplatin (100mg/m2) during surgery and systemic UFT (300mg/day) + PSK (protein-bound polysaccharide, 3g/day) (n=54) and B-Systemic UFT + PSK (n=48). Cisplatin diluted in 1,000 ml of warmed distilled water was injected to the abdominal cavity before closure of the abdomen. Drains were closed for 1 hour after injection of cisplatin. Results: Median follow up was 6.8 years. Postoperative complication rate and side effects were 21.3% and 30.8% in A-arm and 22.4% and 24.0% in B-arm. Tolerance was good in both arms. Peritoneal recurrence rate was 26.9% in A-arm and 40.0% in B-arm (chi-square p=0.16). Overall survival at 5 years was 62.0% and 31.0% in pts with or without hypotonic intraperitoneal cisplatin (log-rank p=0.03). Conclusions: Combining hypotonic intraperitoneal cisplatin and systemic oral chemotherapy improves the efficacy of oral chemotherapy after curative surgery for gastric cancer invading the serosa. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document